Andy Schmeltz is global president and general manager of Pfizer Oncology, responsible for a portfolio of cancer medicines and with a vision to change the trajectory of cancer. Under his leadership, Pfizer Oncology continues to grow, now consisting of 18 medicines and biosimilars that have reached over one million patients. A 16-year Pfizer veteran, Schmeltz was previously head of the Patient and Health Impact division, accountable for ensuring patients gain affordable, timely access to medicines. He also held roles as chief commercial officer for Pfizer Internal Medicine and Pfizer Oncology’s North America regional president. Prior to Pfizer, he spent seven years at Abbott Laboratories in several senior positions.
Previously
Digital systems make it possible to identify patterns and trends in global and domestic health that foster better clinical decision-making and ultimately improve outcomes. Sim...